PUBLICATION
Global Business Reports
United States Biopharmaceuticals 2017
July 27, 2017
A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is framed by uncertainty in light of the country’s recent political transition. Nevertheless, the industry is robust and ready to adapt, already reacting to recent negative media attention relating to drug pricing and price increases. With an increasing amount of innovation stemming from small biotechnology companies and projects spun out from universities into start-ups, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange.
RELATED INTERVIEWS MORE INTERVIEWS
TrialScope helps trial sponsors to comply with disclosure regulations and internal transparency policies for jurisdictions across the world and is developing a program to provide easily intelligible interpretations of trial results for the patients that are involved in trials.
Almac Clinical Technologies designs and deploys complex software that helps trial sponsors automate complex decisions that occur in clinical trials.
UL helps companies meet safety and compliance standards and regulations across the pharma industry.
Chromocell is using its own Chrmovert technology to provide alternative pain blockers to opioids.
RELATED ARTICLES MORE ARTICLES
Quality: A Means for Value Creation
United States Biopharmaceuticals 2017
Firms must shift focus from Quality for Compliance to Quality as a Culture by keeping the end patient in mind.
Regulating Quality
United States Biopharmaceuticals 2017
Maintaining Safeguards Whilst Lowering Barriers to Market Entry.
RECENT PUBLICATIONS
MACIG 2025 - Mining in Africa Country Investment Guide
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
MORE PREVIOUSLY PUBLISHED
It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.
MORE PREVIOUSLY PUBLISHED
MACIG
"Ukwazi means 'to know' in Zulu, and our specialist teams and industry experts integrate multiple knowledge disciplines."
SUBSCRIBE TO OUR NEWSLETTER
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
